"Factor Xa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.
| Descriptor ID |
D015951
|
| MeSH Number(s) |
D08.811.277.656.300.760.315 D08.811.277.656.959.350.315 D12.776.124.125.400.315 D23.119.400.315
|
| Concept/Terms |
Factor Xa- Factor Xa
- Factor Ten A
- Activated Factor X
- Factor X, Activated
- Coagulation Factor Xa
- Factor Xa, Coagulation
- Blood Coagulation Factor X, Activated
- Thrombokinase
- Factor 10A
- Autoprothrombin C
|
Below are MeSH descriptors whose meaning is more general than "Factor Xa".
Below are MeSH descriptors whose meaning is more specific than "Factor Xa".
This graph shows the total number of publications written about "Factor Xa" by people in this website by year, and whether "Factor Xa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Factor Xa" by people in Profiles.
-
In vitro effects of Gla-domainless factor Xa analog on procoagulant and fibrinolytic pathways in apixaban-treated plasma and whole blood. Thromb Res. 2023 Oct; 230:119-125.
-
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.
-
Mechanistic insight into the procoagulant activity of tumor-derived apoptotic vesicles. Biochim Biophys Acta Gen Subj. 2017 Feb; 1861(2):286-295.
-
The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients. J Neurosurg Pediatr. 2015 Sep; 16(3):329-34.
-
Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost. 2013 Jul; 11(7):1287-94.
-
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010 Sep; 104(3):642-9.
-
Factor Xa binding to annexin 2 mediates signal transduction via protease-activated receptor 1. Circ Res. 2008 Feb 29; 102(4):457-64.
-
Regulation of tissue factor--mediated initiation of the coagulation cascade by cell surface grp78. Arterioscler Thromb Vasc Biol. 2005 Aug; 25(8):1737-43.
-
Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1. Blood. 2005 Mar 15; 105(6):2384-91.
-
Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest. 1984 Dec; 74(6):2082-8.